Vaccines Market Size and Growth 2031
Vaccines Market Size and Forecast (2021-2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Type (Conjugated Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, and Toxoid Vaccines), Indication (HPV, PCV, DTP, Hepatitis, Influenza, Dengue, and Others), Route of Administration (Injection, Oral, and Other), Age Group (Pediatric and Adult), and Geography
- Report Date : Jul 2025
- Report Code : TIPRE00015468
- Category : Life Sciences
- Status : Published
- Available Report Formats :
- No. of Pages : 150
The vaccines market size is projected to reach US$ 118.94 billion by 2031 from US$ 80.45 billion in 2024. The market is expected to register a CAGR of 5.7% during 2025–2031. Integration of artificial intelligence and big data in vaccine development is emerging as a significant trend in the vaccines market.
Vaccines Market Analysis
The vaccines market is witnessing substantial growth due to a surge in infectious diseases and heightened public awareness following the COVID‑19 pandemic. Immunization programs across the world have intensified to tackle the rising disease burden from influenza, HPV, and hepatitis. Technological innovation, notably the advent of mRNA, viral-vector, recombinant platforms, AI-driven antigen design, and advanced delivery systems, has accelerated R&D pipelines and enabled rapid, scalable development. Additionally, government funding and policy support play crucial roles: national immunization initiatives, accelerated regulatory pathways, and public–private partnerships such as Gavi and COVAX are lowering barriers and expanding access. Growing healthcare investment in emerging markets, especially Asia Pacific, where expanding middle classes and enhanced infrastructure are boosting uptake, further strengthens market prospects. These factors collectively contribute to the sustained expansion of the vaccines market.
Vaccines Market Overview
The global vaccines market is undergoing accelerated expansion, driven by the expanding burden of infectious diseases, such as influenza, HPV, COVID‑19, and emerging pathogens, emphasizing the urgent demand for preventive healthcare solutions. Key market drivers include cutting-edge innovations in vaccine technologies, notably mRNA, viral-vector, recombinant, and nanotechnology-based platforms, which significantly enhance development speed and efficacy. Additional factors fueling the market growth encompass increasing urbanization and population density, greater uptake of adult and elderly vaccination, use of combination vaccines that simplify immunization schedules. Furthermore, sustained investment in research and development targeting non-infectious diseases—such as cancer and allergies—is broadening the scope and impact of vaccines.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Vaccines Market: Strategic Insights
Market Size Value in US$ 135.28 billion in 2022 Market Size Value by US$ 216.30 billion by 2030 Growth rate CAGR of 6.0% from 2022 to 2030 Forecast Period 2022-2030 Base Year 2022
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Vaccines Market: Strategic Insights
| Market Size Value in | US$ 135.28 billion in 2022 |
| Market Size Value by | US$ 216.30 billion by 2030 |
| Growth rate | CAGR of 6.0% from 2022 to 2030 |
| Forecast Period | 2022-2030 |
| Base Year | 2022 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Vaccines Market Drivers and Opportunities
Surging Immunization Programs and Government Initiatives Bolster Market
Immunization programs offer services that ensure immunity to vaccine-preventable diseases. These services include documenting evidence of immunity, administering immunizations and re-immunizations, and maintaining records for reporting to state or local immunization information systems (IIS), also known as vaccine registries.
The Essential Programme for Immunization (EPI), developed by WHO in 1974, was designed to coordinate the targeted implementation of vaccination through national immunization programs. This initiative has been instrumental in expanding global vaccine access. Additionally, the establishment of Gavi, the Vaccine Alliance, an independent multilateral funding mechanism in 2000, aimed at increasing global access to vaccines, has played a critical role in facilitating vaccine introduction in low- and middle-income countries (LMICs). According to an article published in the Journal of Infectious Diseases in October 2021, it is estimated that vaccine access has prevented at least 37 million deaths in 98 LMICs by protecting against 10 vaccine-preventable diseases, including Haemophilus influenzae type B, Japanese encephalitis, Neisseria meningitidis serogroup A, measles, Streptococcus pneumoniae, rotavirus, rubella, and yellow fever.
The World Health Assembly, with the support of various countries and partners, launched a strategy called the Immunization Agenda 2030 in 2020. This initiative aims to address vaccination challenges and save over 50 million lives by 2030. In the US, vaccination initiatives are diverse and include federal programs like the Vaccines for Children program, as well as state and local efforts and partnerships with various organizations. As the programs aim to increase vaccination rates, ensure equitable access to vaccines, and combat diseases that can be prevented through vaccination, the vaccines market continues to grow at a significant rate.
Development of Combination and Therapeutic Vaccines to Create Growth Opportunities
The vaccine industry is currently experiencing a transformative phase, with combination and therapeutic vaccines emerging as the most promising opportunities for manufacturers. Innovations in these vaccines not only address evolving public health challenges but also provide significant commercial and operational advantages.
Combination vaccines are formulations designed to protect against multiple diseases in a single shot. Traditionally used in pediatric care, as seen with vaccines like MMR (measles, mumps, rubella) and DTP (diphtheria, tetanus, pertussis), combination vaccines are now expanding their reach to adult and elderly populations. This is particularly relevant for respiratory illnesses such as influenza, COVID-19, and Respiratory Syncytial Virus (RSV). Combination vaccines can greatly improve immunization rates, resulting in a quicker and more extensive reduction in disease burden. They are especially important as new vaccines for diseases such as dengue, typhoid, RSV, and tuberculosis are being developed. According to Gavi, by 2030, combination vaccines will provide protection against 30 infections with fewer doses.
Major pharmaceutical companies, including Moderna, Pfizer/BioNTech, Novavax, Sanofi, GSK, and AstraZeneca, are developing combination vaccines for COVID-19, influenza, and RSV. These products are anticipated to transform seasonal immunization strategies and enhance uptake among adults and elderly populations. In June 2025, Moderna, Inc. announced that the US Food and Drug Administration (FDA) approved mRESVIA (mRNA-1345), the company's RSV vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals aged 18–59 years who are at increased risk for disease. This approval expanded the previous indication of mRESVIA, which was approved in May 2024 for adults aged 60 years and older.
Additionally, therapeutic vaccines are designed not to prevent diseases but to treat existing conditions, which can include chronic infections, cancers, and allergies. This approach represents a new frontier in vaccine technology, utilizing advancements in mRNA, viral vectors, and personalized medicine. For instance, cancer vaccines aim to stimulate the immune system to recognize and attack tumor cells. Additionally, some vaccines are being developed for chronic infections such as hepatitis B and HIV. As of 2024, the US Food and Drug Administration (FDA) has approved three therapeutic vaccines: Sipuleucel-T for advanced prostate cancer, Bacillus Calmette-Guérin for high-risk, non-muscle-invasive bladder cancer, and Talimogene laherparepvec for melanoma. Therefore, the development of combination and therapeutic vaccines presents substantial opportunities for vaccine manufacturers to grow, innovate, and create a meaningful impact. These vaccines simplify immunization, expand their applications, and address both preventive and therapeutic health needs worldwide.
Vaccines Market Report Segmentation Analysis
Key segments that are the foundation of vaccines market analysis are type, indication, route of administration, and age group.
- Based on type, the vaccines market is segmented into conjugated vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. The conjugated vaccines segment held the largest share of the market in 2024.
- In terms of indication, the vaccines market is categorized into HPV, PCV, DTP, hepatitis, influenza, dengue, and others. The HPV segment dominated the market in 2024.
- By route of administration, the market is classified into injection, oral, and other. The injection segment dominated the vaccines market share in 2024.
- In terms of age group, the vaccines market is bifurcated into pediatric and adult. The pediatric segment dominated the market in 2024.
Vaccines Market Share Analysis by Geography
The geographical scope of the vaccines market report is divided into five regions: North America, Asia Pacific, Europe, the Middle East and Africa, and South and Central America.
North America held a significant share of the market in 2024. A primary catalyst is the increase in cases of infectious diseases, which has created sustained demand for preventive healthcare solutions, including vaccines. Mass immunization programs for the prevention of infectious diseases drive the need for vaccines on a large scale, owing to which several initiatives and strategies are being encouraged to enhance vaccine production facilities in North America. Moreover, private sector partnerships, international collaborations, and increased funding from both government and non-government organizations have fueled the pipeline for new vaccine candidates. Rising awareness about travel-related vaccinations and the resurgence of preventable diseases such as measles due to vaccine hesitancy have also spotlighted the importance of immunization, thereby stimulating market growth.
Vaccines Market Report Scope
Vaccines Market News and Recent Developments
The vaccines market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A key development in the market is listed below:
- Serum Institute of India, the world’s largest vaccine manufacturer by dose volume, entered into an exclusive global agreement with ImmunityBio, Inc., to supply Bacillus Calmette-Guerin (BCG) to ImmunityBio. The deal includes the production of standard BCG, approved for use outside the US, as well as a next-generation recombinant BCG (iBCG), currently undergoing testing. The two companies collaborate to expedite the Phase 2 clinical trials of iBCG being conducted in Europe. (Source: Serum Institute of India Pvt. Ltd., Press Release, May 2024)
- GSK entered into an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to help protect Canadian adults and children. The four-year agreement, spanning through March 2026, includes the supply of as many as 80 million doses of Arepanrix (adjuvanted pandemic influenza vaccine) in the event of an influenza pandemic(s) and a minimum of 4 million doses per year of Flulaval Tetra (seasonal influenza vaccine). (Source: GlaxoSmithKline plc., Press Release, July 2022)
Vaccines Market Report Coverage and Deliverables
The "Vaccines Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
- Vaccines market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Vaccines market trends and market dynamics, such as drivers, restraints, and key opportunities
- Detailed PEST and SWOT analysis
- Vaccines market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments in the vaccines market
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Technology, Application, Route of Administration, End User, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
North America dominated the market in 2024.
The growing incidences of infectious diseases and disease outbreaks, and surging immunization programs and government initiatives contribute to market growth.
GlaxoSmithKline plc, Sanofi SA, CSL Seqirus, Abbott, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd, Pfizer Inc., Mylan NV, Novartis, and Merck are among the key players operating in the vaccines market.
The market is expected to reach US$ 118.94 billion by 2031.
The market is estimated to register a CAGR of 5.7% during the forecast period.
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Analyst Market Outlook
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:
3.3 Assumptions and Limitations
4. Vaccines Market Landscape
4.1 Overview
4.2 PEST Analysis
5. Vaccines Market – Key Market Dynamics
5.1 Vaccines Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Growing Incidences of Infectious Diseases and Disease Outbreaks
5.2.2 Surging Immunization Programs and Government Initiatives
5.3 Market Restraints
5.3.1 High Vaccine Development Cost and Increased Time to Market
5.4 Market Opportunities
5.4.1 Development of Combination and Therapeutic Vaccines
5.5 Future Trends
5.5.1 Integration of Artificial Intelligence and Big Data in Vaccine Development
5.6 Impact of Drivers and Restraints:
6. Vaccines Market - Global Market Analysis
6.1 Vaccines - Global Market Overview
6.2 Vaccines - Global Market and Forecast to 2031
7. Vaccines Market – Revenue Analysis (USD Million) – By Technology, 2020-2031
7.1 Overview
7.2 Live Attenuated Vaccines
7.1.1 Overview
7.1.2 Live Attenuated Vaccines: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Inactivated Vaccines and Subunit Vaccines
7.2.1 Overview
7.2.2 Inactivated Vaccines and Subunit Vaccines: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Toxoid Vaccines
7.3.1 Overview
7.3.2 Toxoid Vaccines: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Conjugate Vaccines
7.3.1 Overview
7.3.2 Conjugate Vaccines: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
7.6 Recombinant Vaccines
7.3.1 Overview
7.3.2 Recombinant Vaccines: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
7.7 Others
8. Vaccines Market – Revenue Analysis (USD Million) – By Disease Indication, 2020-2031
8.1 Overview
8.2 Influenza
8.1.1 Overview
8.1.2 Influenza: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Dengue
8.1.1 Overview
8.1.2 Dengue: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Cytomegalovirus (CMV)
8.1.1 Overview
8.1.2 Cytomegalovirus (CMV): Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
8.5 Hepatitis
8.1.1 Overview
8.1.2 Hepatitis: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
8.6 Respiratory Synical Virus (RSV)
8.1.1 Overview
8.1.2 Respiratory Synical Virus (RSV): Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
8.7 Other Diseases
8.1.1 Overview
8.1.2 Other Diseases: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
9. Vaccines Market – Revenue Analysis (USD Million) – By Route of Administration, 2020-2031
9.1 Overview
9.1.1 Overview
9.1.2 Oral: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
9.3 Injectable
9.1.1 Overview
9.1.2 Injectable: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
9.4 Other Route of Administration
9.1.1 Overview
9.1.2 Other Route of Administration: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
10. Vaccines Market – Revenue Analysis (USD Million) – By Patient Type, 2020-2031
10.1 Overview
10.2 Pediatric
10.2.1 Overview
10.2.2 Pediatric: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
10.3 Adult
10.3.1 Overview
10.3.2 Adult: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
11. Vaccines Market - Revenue Analysis (USD Million), 2020-2031 – Geographical Analysis
11.1 North America
11.1.1 North America Vaccines Market Overview
11.1.2 North America Vaccines Market Revenue and Forecasts to 2031
11.1.3 North America Vaccines Market Revenue and Forecasts and Analysis - By Technology
11.1.4 North America Vaccines Market Revenue and Forecasts and Analysis - By Disease Indication
11.1.5 North America Vaccines Market Revenue and Forecasts and Analysis - By Route of Administration
11.1.6 North America Vaccines Market Revenue and Forecasts and Analysis - By Patient Type
11.1.7 North America Vaccines Market Revenue and Forecasts and Analysis - By Countries
11.1.7.1 United States Vaccines Market
11.1.7.1.1 United States Vaccines Market, by Technology
11.1.7.1.2 United States Vaccines Market, by Disease Indication
11.1.7.1.3 United States Vaccines Market, by Route of Administration
11.1.7.1.4 United States Vaccines Market, by Patient Type
11.1.7.2 Canada Vaccines Market
11.1.7.2.1 Canada Vaccines Market, by Technology
11.1.7.2.2 Canada Vaccines Market, by Disease Indication
11.1.7.2.3 Canada Vaccines Market, by Route of Administration
11.1.7.2.4 Canada Vaccines Market, by Patient Type
11.1.7.3 Mexico Vaccines Market
11.1.7.3.1 Mexico Vaccines Market, by Technology
11.1.7.3.2 Mexico Vaccines Market, by Disease Indication
11.1.7.3.3 Mexico Vaccines Market, by Route of Administration
11.1.7.3.4 Mexico Vaccines Market, by Patient Type
Note - Similar analysis would be provided for below mentioned regions/countries
11.2 Europe
10.2.1 Europe Vaccines Market Overview
10.2.2 Europe: Vaccines Market – Revenue, 2021–2031 (US$ Million)
10.2.2.1 Europe: Vaccines Market – Revenue and Forecast Analysis – by Technology
10.2.2.2 Europe: Vaccines Market – Revenue and Forecast Analysis – by Live Attenuated Vaccines
10.2.2.3 Europe: Vaccines Market – Revenue and Forecast Analysis – by Inactivated Vaccines and Subunit Vaccines
10.2.2.4 Europe: Vaccines Market – Revenue and Forecast Analysis – by Disease Indication
10.2.2.5 Europe: Vaccines Market – Revenue and Forecast Analysis – by Influenza
10.2.2.6 Europe: Vaccines Market – Revenue and Forecast Analysis – by Route of Administration
10.2.3 Europe: Vaccines Market – Revenue and Forecast Analysis – by Country
10.2.3.1 Germany: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.3.1.1 Germany: Vaccines Market Breakdown, by Technology
10.2.3.1.2 Germany: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.2.3.1.3 Germany: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.2.3.1.4 Germany: Vaccines Market Breakdown, by Disease Indication
10.2.3.1.5 Germany: Vaccines Market Breakdown, by Influenza
10.2.3.1.6 Germany: Vaccines Market Breakdown, by Route of Administration
10.2.3.2 United Kingdom: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.3.2.1 United Kingdom: Vaccines Market Breakdown, by Technology
10.2.3.2.2 United Kingdom: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.2.3.2.3 United Kingdom: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.2.3.2.4 United Kingdom: Vaccines Market Breakdown, by Disease Indication
10.2.3.2.5 United Kingdom: Vaccines Market Breakdown, by Influenza
10.2.3.2.6 United Kingdom: Vaccines Market Breakdown, by Route of Administration
10.2.3.3 France: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.3.3.1 France: Vaccines Market Breakdown, by Technology
10.2.3.3.2 France: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.2.3.3.3 France: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.2.3.3.4 France: Vaccines Market Breakdown, by Disease Indication
10.2.3.3.5 France: Vaccines Market Breakdown, by Influenza
10.2.3.3.6 France: Vaccines Market Breakdown, by Route of Administration
10.2.3.4 Italy: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.3.4.1 Italy: Vaccines Market Breakdown, by Technology
10.2.3.4.2 Italy: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.2.3.4.3 Italy: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.2.3.4.4 Italy: Vaccines Market Breakdown, by Disease Indication
10.2.3.4.5 Italy: Vaccines Market Breakdown, by Influenza
10.2.3.4.6 Italy: Vaccines Market Breakdown, by Route of Administration
10.2.3.5 Spain: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.3.5.1 Spain: Vaccines Market Breakdown, by Technology
10.2.3.5.2 Spain: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.2.3.5.3 Spain: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.2.3.5.4 Spain: Vaccines Market Breakdown, by Disease Indication
10.2.3.5.5 Spain: Vaccines Market Breakdown, by Influenza
10.2.3.5.6 Spain: Vaccines Market Breakdown, by Route of Administration
10.2.3.6 Rest of Europe: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.2.3.6.1 Rest of Europe: Vaccines Market Breakdown, by Technology
10.2.3.6.2 Rest of Europe: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.2.3.6.3 Rest of Europe: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.2.3.6.4 Rest of Europe: Vaccines Market Breakdown, by Disease Indication
10.2.3.6.5 Rest of Europe: Vaccines Market Breakdown, by Influenza
10.2.3.6.6 Rest of Europe: Vaccines Market Breakdown, by Route of Administration
10.3 Asia Pacific
10.3.1 Asia Pacific Vaccines Market Overview
10.3.2 Asia Pacific: Vaccines Market – Revenue, 2021–2031 (US$ Million)
10.3.2.1 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Technology
10.3.2.2 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Live Attenuated Vaccines
10.3.2.3 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Inactivated Vaccines and Subunit Vaccines
10.3.2.4 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Disease Indication
10.3.2.5 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Influenza
10.3.2.6 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Route of Administration
10.3.3 Asia Pacific: Vaccines Market – Revenue and Forecast Analysis – by Country
10.3.3.1 China: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.3.1.1 China: Vaccines Market Breakdown, by Technology
10.3.3.1.2 China: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.3.3.1.3 China: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.3.3.1.4 China: Vaccines Market Breakdown, by Disease Indication
10.3.3.1.5 China: Vaccines Market Breakdown, by Influenza
10.3.3.1.6 China: Vaccines Market Breakdown, by Route of Administration
10.3.3.2 India: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.3.2.1 India: Vaccines Market Breakdown, by Technology
10.3.3.2.2 India: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.3.3.2.3 India: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.3.3.2.4 India: Vaccines Market Breakdown, by Disease Indication
10.3.3.2.5 India: Vaccines Market Breakdown, by Influenza
10.3.3.2.6 India: Vaccines Market Breakdown, by Route of Administration
10.3.3.3 Japan: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.3.3.1 Japan: Vaccines Market Breakdown, by Technology
10.3.3.3.2 Japan: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.3.3.3.3 Japan: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.3.3.3.4 Japan: Vaccines Market Breakdown, by Disease Indication
10.3.3.3.5 Japan: Vaccines Market Breakdown, by Influenza
10.3.3.3.6 Japan: Vaccines Market Breakdown, by Route of Administration
10.3.3.4 Australia: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.3.4.1 Australia: Vaccines Market Breakdown, by Technology
10.3.3.4.2 Australia: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.3.3.4.3 Australia: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.3.3.4.4 Australia: Vaccines Market Breakdown, by Disease Indication
10.3.3.4.5 Australia: Vaccines Market Breakdown, by Influenza
10.3.3.4.6 Australia: Vaccines Market Breakdown, by Route of Administration
10.3.3.5 South Korea: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.3.5.1 South Korea: Vaccines Market Breakdown, by Technology
10.3.3.5.2 South Korea: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.3.3.5.3 South Korea: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.3.3.5.4 South Korea: Vaccines Market Breakdown, by Disease Indication
10.3.3.5.5 South Korea: Vaccines Market Breakdown, by Influenza
10.3.3.5.6 South Korea: Vaccines Market Breakdown, by Route of Administration
10.3.3.6 Rest of APAC: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.3.3.6.1 Rest of APAC: Vaccines Market Breakdown, by Technology
10.3.3.6.2 Rest of APAC: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.3.3.6.3 Rest of APAC: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.3.3.6.4 Rest of APAC: Vaccines Market Breakdown, by Disease Indication
10.3.3.6.5 Rest of APAC: Vaccines Market Breakdown, by Influenza
10.3.3.6.6 Rest of APAC: Vaccines Market Breakdown, by Route of Administration
10.4 Middle East and Africa
10.4.1 Middle East and Africa Vaccines Market Overview
10.4.2 Middle East and Africa: Vaccines Market – Revenue, 2021–2031 (US$ Million)
10.4.2.1 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis – by Technology
10.4.2.2 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis – by Live Attenuated Vaccines
10.4.2.3 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis – by Inactivated Vaccines and Subunit Vaccines
10.4.2.4 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis – by Disease Indication
10.4.2.5 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis – by Influenza
10.4.2.6 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis – by Route of Administration
10.4.3 Middle East and Africa: Vaccines Market – Revenue and Forecast Analysis – by Country
10.4.3.1 South Africa: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.3.1.1 South Africa: Vaccines Market Breakdown, by Technology
10.4.3.1.2 South Africa: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.4.3.1.3 South Africa: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.4.3.1.4 South Africa: Vaccines Market Breakdown, by Disease Indication
10.4.3.1.5 South Africa: Vaccines Market Breakdown, by Influenza
10.4.3.1.6 South Africa: Vaccines Market Breakdown, by Route of Administration
10.4.3.2 Saudi Arabia: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.3.2.1 Saudi Arabia: Vaccines Market Breakdown, by Technology
10.4.3.2.2 Saudi Arabia: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.4.3.2.3 Saudi Arabia: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.4.3.2.4 Saudi Arabia: Vaccines Market Breakdown, by Disease Indication
10.4.3.2.5 Saudi Arabia: Vaccines Market Breakdown, by Influenza
10.4.3.2.6 Saudi Arabia: Vaccines Market Breakdown, by Route of Administration
10.4.3.3 United Arab Emirates: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.3.3.1 United Arab Emirates: Vaccines Market Breakdown, by Technology
10.4.3.3.2 United Arab Emirates: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.4.3.3.3 United Arab Emirates: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.4.3.3.4 United Arab Emirates: Vaccines Market Breakdown, by Disease Indication
10.4.3.3.5 United Arab Emirates: Vaccines Market Breakdown, by Influenza
10.4.3.3.6 United Arab Emirates: Vaccines Market Breakdown, by Route of Administration
10.4.3.4 Rest of Middle East and Africa: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.4.3.4.1 Rest of Middle East and Africa: Vaccines Market Breakdown, by Technology
10.4.3.4.2 Rest of Middle East and Africa: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.4.3.4.3 Rest of Middle East and Africa: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.4.3.4.4 Rest of Middle East and Africa: Vaccines Market Breakdown, by Disease Indication
10.4.3.4.5 Rest of Middle East and Africa: Vaccines Market Breakdown, by Influenza
10.4.3.4.6 Rest of Middle East and Africa: Vaccines Market Breakdown, by Route of Administration
10.5 South and Central America
10.5.1 South and Central America Vaccines Market Overview
10.5.2 South and Central America: Vaccines Market – Revenue, 2021–2031 (US$ Million)
10.5.2.1 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Technology
10.5.2.2 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Live Attenuated Vaccines
10.5.2.3 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Inactivated Vaccines and Subunit Vaccines
10.5.2.4 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Disease Indication
10.5.2.5 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Influenza
10.5.2.6 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Route of Administration
10.5.3 South and Central America: Vaccines Market – Revenue and Forecast Analysis – by Country
10.5.3.1 Brazil: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.5.3.1.1 Brazil: Vaccines Market Breakdown, by Technology
10.5.3.1.2 Brazil: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.5.3.1.3 Brazil: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.5.3.1.4 Brazil: Vaccines Market Breakdown, by Disease Indication
10.5.3.1.5 Brazil: Vaccines Market Breakdown, by Influenza
10.5.3.1.6 Brazil: Vaccines Market Breakdown, by Route of Administration
10.5.3.2 Argentina: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.5.3.2.1 Argentina: Vaccines Market Breakdown, by Technology
10.5.3.2.2 Argentina: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.5.3.2.3 Argentina: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.5.3.2.4 Argentina: Vaccines Market Breakdown, by Disease Indication
10.5.3.2.5 Argentina: Vaccines Market Breakdown, by Influenza
10.5.3.2.6 Argentina: Vaccines Market Breakdown, by Route of Administration
10.5.3.3 Rest of South and Central America: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
10.5.3.3.1 Rest of South and Central America: Vaccines Market Breakdown, by Technology
10.5.3.3.2 Rest of South and Central America: Vaccines Market Breakdown, by Live Attenuated Vaccines
10.5.3.3.3 Rest of South and Central America: Vaccines Market Breakdown, by Inactivated Vaccines and Subunit Vaccines
10.5.3.3.4 Rest of South and Central America: Vaccines Market Breakdown, by Disease Indication
10.5.3.3.5 Rest of South and Central America: Vaccines Market Breakdown, by Influenza
10.5.3.3.6 Rest of South and Central America: Vaccines Market Breakdown, by Route of Administration
12. Industry Landscape
12.1 Mergers and Acquisitions
12.2 Agreements, Collaborations, Joint Ventures
12.3 New Product Launches
12.4 Expansions and Other Strategic Developments
13. Competitive Landscape
13.1 Heat Map Analysis by Key Players
13.2 Ranking by Key Players
14. Vaccines Market - Key Company Profiles
14.1 GlaxoSmithKline plc
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc.
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Sanofi
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Merck and Co., Inc
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Serum Institute of India (SII)
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 BioNTech
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Abbott
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Sinovac
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Novartis
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 CSL Seqirus
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 Glossary
15.2 About The Insight Partners
15.3 Market Intelligence Cloud
List of Tables
Table 1. Vaccines Market Segmentation
Table 2. Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 3. Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 4. North America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 5. North America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 6. North America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 7. North America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 8. North America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 9. North America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 10. North America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 11. North America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 12. North America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 13. North America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 14. North America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 15. North America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 16. United States: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 17. United States: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 18. United States: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 19. United States: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 20. United States: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 21. United States: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 22. United States: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 23. United States: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 24. United States: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 25. United States: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 26. United States: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 27. United States: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 28. Canada: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 29. Canada: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 30. Canada: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 31. Canada: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 32. Canada: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 33. Canada: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 34. Canada: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 35. Canada: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 36. Canada: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 37. Canada: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 38. Canada: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 39. Canada: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 40. Mexico: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 41. Mexico: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 42. Mexico: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 43. Mexico: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 44. Mexico: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 45. Mexico: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 46. Mexico: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 47. Mexico: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 48. Mexico: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 49. Mexico: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 50. Mexico: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 51. Mexico: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 52. Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 53. Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 54. Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 55. Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 56. Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 57. Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 58. Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 59. Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 60. Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 61. Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 62. Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 63. Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 64. Germany: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 65. Germany: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 66. Germany: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 67. Germany: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 68. Germany: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 69. Germany: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 70. Germany: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 71. Germany: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 72. Germany: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 73. Germany: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 74. Germany: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 75. Germany: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 76. United Kingdom: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 77. United Kingdom: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 78. United Kingdom: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 79. United Kingdom: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 80. United Kingdom: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 81. United Kingdom: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 82. United Kingdom: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 83. United Kingdom: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 84. United Kingdom: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 85. United Kingdom: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 86. United Kingdom: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 87. United Kingdom: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 88. France: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 89. France: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 90. France: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 91. France: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 92. France: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 93. France: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 94. France: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 95. France: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 96. France: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 97. France: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 98. France: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 99. France: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 100. Italy: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 101. Italy: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 102. Italy: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 103. Italy: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 104. Italy: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 105. Italy: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 106. Italy: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 107. Italy: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 108. Italy: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 109. Italy: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 110. Italy: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 111. Italy: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 112. Spain: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 113. Spain: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 114. Spain: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 115. Spain: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 116. Spain: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 117. Spain: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 118. Spain: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 119. Spain: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 120. Spain: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 121. Spain: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 122. Spain: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 123. Spain: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 124. Rest of Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 125. Rest of Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 126. Rest of Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 127. Rest of Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 128. Rest of Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 129. Rest of Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 130. Rest of Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 131. Rest of Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 132. Rest of Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 133. Rest of Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 134. Rest of Europe: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 135. Rest of Europe: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 136. Asia Pacific: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 137. Asia Pacific: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 138. Asia Pacific: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 139. Asia Pacific: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 140. Asia Pacific: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 141. Asia Pacific: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 142. Asia Pacific: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 143. Asia Pacific: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 144. Asia Pacific: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 145. Asia Pacific: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 146. Asia Pacific: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 147. Asia Pacific: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 148. China: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 149. China: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 150. China: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 151. China: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 152. China: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 153. China: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 154. China: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 155. China: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 156. China: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 157. China: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 158. China: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 159. China: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 160. India: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 161. India: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 162. India: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 163. India: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 164. India: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 165. India: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 166. India: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 167. India: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 168. India: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 169. India: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 170. India: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 171. India: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 172. Japan: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 173. Japan: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 174. Japan: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 175. Japan: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 176. Japan: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 177. Japan: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 178. Japan: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 179. Japan: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 180. Japan: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 181. Japan: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 182. Japan: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 183. Japan: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 184. Australia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 185. Australia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 186. Australia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 187. Australia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 188. Australia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 189. Australia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 190. Australia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 191. Australia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 192. Australia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 193. Australia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 194. Australia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 195. Australia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 196. South Korea: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 197. South Korea: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 198. South Korea: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 199. South Korea: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 200. South Korea: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 201. South Korea: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 202. South Korea: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 203. South Korea: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 204. South Korea: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 205. South Korea: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 206. South Korea: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 207. South Korea: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 208. Rest of APAC: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 209. Rest of APAC: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 210. Rest of APAC: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 211. Rest of APAC: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 212. Rest of APAC: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 213. Rest of APAC: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 214. Rest of APAC: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 215. Rest of APAC: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 216. Rest of APAC: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 217. Rest of APAC: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 218. Rest of APAC: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 219. Rest of APAC: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 220. Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 221. Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 222. Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 223. Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 224. Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 225. Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 226. Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 227. Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 228. Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 229. Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 230. Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 231. Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 232. South Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 233. South Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 234. South Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 235. South Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 236. South Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 237. South Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 238. South Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 239. South Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 240. South Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 241. South Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 242. South Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 243. South Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 244. Saudi Arabia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 245. Saudi Arabia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 246. Saudi Arabia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 247. Saudi Arabia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 248. Saudi Arabia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 249. Saudi Arabia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 250. Saudi Arabia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 251. Saudi Arabia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 252. Saudi Arabia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 253. Saudi Arabia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 254. Saudi Arabia: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 255. Saudi Arabia: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 256. United Arab Emirates: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 257. United Arab Emirates: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 258. United Arab Emirates: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 259. United Arab Emirates: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 260. United Arab Emirates: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 261. United Arab Emirates: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 262. United Arab Emirates: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 263. United Arab Emirates: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 264. United Arab Emirates: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 265. United Arab Emirates: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 266. United Arab Emirates: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 267. United Arab Emirates: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 268. Rest of Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 269. Rest of Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 270. Rest of Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 271. Rest of Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 272. Rest of Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 273. Rest of Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 274. Rest of Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 275. Rest of Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 276. Rest of Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 277. Rest of Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 278. Rest of Middle East and Africa: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 279. Rest of Middle East and Africa: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 280. South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 281. South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 282. South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 283. South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 284. South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 285. South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 286. South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 287. South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 288. South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 289. South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 290. South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 291. South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 292. Brazil: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 293. Brazil: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 294. Brazil: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 295. Brazil: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 296. Brazil: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 297. Brazil: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 298. Brazil: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 299. Brazil: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 300. Brazil: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 301. Brazil: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 302. Brazil: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 303. Brazil: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 304. Argentina: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 305. Argentina: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 306. Argentina: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 307. Argentina: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 308. Argentina: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 309. Argentina: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 310. Argentina: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 311. Argentina: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 312. Argentina: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 313. Argentina: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 314. Argentina: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 315. Argentina: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 316. Rest of South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Technology
Table 317. Rest of South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Technology
Table 318. Rest of South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Live Attenuated Vaccines
Table 319. Rest of South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Live Attenuated Vaccines
Table 320. Rest of South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 321. Rest of South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Inactivated Vaccines and Subunit Vaccines
Table 322. Rest of South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Disease Indication
Table 323. Rest of South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Disease Indication
Table 324. Rest of South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Influenza
Table 325. Rest of South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Influenza
Table 326. Rest of South and Central America: Vaccines Market – Revenue, 2021–2024 (US$ Million) – by Route of Administration
Table 327. Rest of South and Central America: Vaccines Market – Revenue Forecast, 2025–2031 (US$ Million) – by Route of Administration
Table 328. Glossary of Terms, Vaccines Market
List of Figures
Figure 1. Vaccines Market Segmentation, by Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Vaccines Market Revenue (US$ Million), 2021–2031
Figure 5. Vaccines Market Revenue (US$ Million), 2021–2031
Figure 6. Vaccines Market Share (%) – by Technology (2024 and 2031)
Figure 7. Live Attenuated Vaccines: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. Livestock and Poultry: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
Figure 9. Vaccines Market Share (%) – by Disease Indication (2024 and 2031)
Figure 10. Influenza: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
Figure 11. Medical Devices: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
Figure 12. Feed Additives: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Vaccines Market Share (%) – by Route of Administration (2024 and 2031)
Figure 14. Veterinary Hospitals: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
Figure 15. Clinics: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
Figure 16. Others: Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
Figure 17. North America: Vaccines Market – Revenue, 2021–2031 (US$ Million)
Figure 18. North America: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 19. United States: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 20. Canada: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 21. Mexico: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 22. Europe: Vaccines Market – Revenue, 2021–2031 (US$ Million)
Figure 23. Europe: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 24. Germany: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 25. United Kingdom: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 26. France: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 27. Italy: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 28. Spain: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 29. Rest of Europe: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 30. Asia Pacific: Vaccines Market – Revenue, 2021–2031 (US$ Million)
Figure 31. Asia Pacific: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 32. China: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 33. India: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 34. Japan: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 35. Australia: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 36. South Korea: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 37. Rest of APAC: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 38. Middle East and Africa: Vaccines Market – Revenue, 2021–2031 (US$ Million)
Figure 39. Middle East and Africa: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 40. South Africa: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 41. Saudi Arabia: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 42. United Arab Emirates: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 43. Rest of Middle East and Africa: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 44. South and Central America: Vaccines Market – Revenue, 2021–2031 (US$ Million)
Figure 45. South and Central America: Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 46. Brazil: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 47. Argentina: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 48. Rest of South and Central America: Vaccines Market – Revenue and Forecast, 2021–2031 (US$ Million)
The List of Companies - Vaccines Market
- GlaxoSmithKline plc
- Sanofi SA
- CSL Seqirus
- Abbott
- Serum Institute of India Pvt. Ltd.
- Sinovac Biotech Ltd
- Pfizer Inc
- Mylan NV
- Novartis
- Merck
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Jul 2025
Infectious Disease In vitro Diagnostics Market
Size and Forecast (2021-2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Application (HIV or AIDS, Tuberculosis, Hepatitis B and C, Malaria, and Others), End User (Hospitals and Clinics, Diagnostic Laboratories, Blood Bank, and Others), and Geography
Jul 2025
Donor Blood Components Market
Size and Forecast (2021–2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Blood Component (Red Blood Cells, White Blood Cells, Platelets, Plasma, and Others), Indication (Immunosuppression and Oncology), Application (Anemia Management, Thrombocytopenia Treatment, Coagulopathy Correction, Supportive Care During Chemotherapy, Surgery, and Others), Age Group (Adult and Child), End User (Hospitals, Oncology Centers, Transplant Centers, Ambulatory Surgical Centers, and Others), and Geography
Jul 2025
Aesthetic Injectable Devices Market
Size and Forecast (2021-2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Product (Dermal Filler, Botulinum Toxin and Others), Dermal Fillers (Calcium Hydroxylapatite, Hyaluronic Acid, Collagen, Poly-L-Lactic Acid, Polymethylmethacrylate, Fat Fillers, and Others), Device Type (Microcannulas, Pre-Filled Syringes, Mesotherapy Guns, and Others), Application (Facial Line Correction, Face Lift, Lip Treatment, Anti-Ageing and Wrinkle Treatment, Acne and Scar Treatment, Stretch Marks, and Others), Age Group (Up to 30, 31-40, 41-50, 51-60, and More Than 60), Gender (Female and Male), End User (Medical Spas, Dermatology Clinics, Hospitals, and Others), and Geography
Jul 2025
ECG Monitoring Equipment Market
Size and Forecast (2021-2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Resting ECG, Stress ECG, Holter Monitors, and Cardiopulmonary Stress Testing Monitors), Lead Type (12-Lead ECG, 3–6 Lead ECG, and Single Lead), Technology [Portable (Wired) ECG System and Wireless ECG System], End User (Hospital and Clinics, Ambulatory Surgical Centers, Cardiac Centers, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jul 2025
Prescription Drugs Market
Size and Forecast (2021-2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: Product Type (Branded and Generics), Drug Type (Small Molecule and Biologics and Biosimilar), Therapeutic Area (Oncology, Cardiovascular Diseases, Neurological Diseases, Metabolic Diseases, Respiratory Diseases, Immunology, and Others), Route Of Administration (Oral, Injectable, Topical, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jul 2025
Regenerative Dentistry Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Natural and Synthetic), Technology (Tissue Engineering, Stem Cell Therapy, and Others), Application (Periodontal Regeneration, Endodontic Regeneration, Tooth Reconstruction, Bone Regeneration, and Others), Age Group (Adult and Pediatric), End User (Dental Clinics, Hospital, and Others), and Geography
Jul 2025
Wound Closure Devices Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Sutures, Adhesives, Staplers, Strips, and Others), Wound Type (Chronic Wound and Acute Wound), End User (Hospitals, Clinics, Ambulatory Surgery Centers, and Others), and Geography
Jul 2025
Cell and Gene Therapy Contract Development and Manufacturing Organization Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Service Type (Drug Development and Manufacturing, Testing and Regulatory Services, and Others), Product Type (Gene Therapy and Cell Therapy), End User (Pharmaceutical Companies, Biopharmaceutical Companies, and Others), and Geography
Get Free Sample For